MENU

Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials

The data bolsters Eli Lilly's position in the budding weight loss drug market and establishes the company as a formidable competitor to Novo Nordisk.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story